Reuters: Regulatory News: Medivation prostate cancer drug gets priority review

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Medivation prostate cancer drug gets priority review Jul 24th 2012, 11:51 July 24 | Tue Jul 24, 2012 7:51am EDT July 24 (Reuters) - Medivation Inc's experimental prostate cancer drug enzalutamide was granted priority review status by the U.S. Food and Drug Administration, potentially reducing the review time by half. The drug, formerly called MDV3100, was developed in partnership with Japan's Astellas Pharma Inc for the treatment of men with castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy. The acceptance of the drug for review triggered a $10 million milestone payment to Medivation from Astellas, the companies said in a joint statement. Prostate cancer kills about 250,000 men a year globally and the market for drugs to treat the disease is expected to grow to more than $10 billion in 2020, according to market research firm Decision Resources. New and potential treatments for the deadly cancer are watched closely by industry analysts and investors alike. Drugs on the market include Johnson & Johnson's Zytiga and Dendreon Corp's vaccine Provenge. Bayer AG is also developing an experimental drug called alpharadin. Medivation shares closed at $93.27 Monday on the Nasdaq.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions